2023 Fiscal Year Final Research Report
Elucidation of relapse type-dependent ctDNA dynamics on multiple tumor origins
| Project/Area Number |
21K07223
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
開 勇人 岩手医科大学, 医歯薬総合研究所, 助教 (50847358)
岩谷 岳 岩手医科大学, 医学部, 特任教授 (70405801)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | ctDNA / cancer / therapy |
|---|
| Outline of Final Research Achievements |
This study was initiated for elucidating the clinical validity of circulating tumor DNA (ctDNA). In our laboratory, the ctDNA monitoring system has been established by primary sequencing followed by the ctDNA monitoring using originally developed digital PCR (dPCR) primer/probe library. A two-year observation for enrolled 314 patients was completed on May 2023. Total time points for ctDNA monitoring is 2,500. Panel sequencing of primary samples has completed for 314 cases whereas dPCR for ctDNA analysis has carried out for 218 cases. Ninety-six per cent of clinical data input during cancer therapy were completed whereas 1,500 imaging data from CT/MRI were obtained as a categorical format. Upon finalizing data integration, dynamics of ctDNA monitoring will be analyzed in views across organs, drugs, genes, and types of relapse formation.
|
| Free Research Field |
Biomarker
|
| Academic Significance and Societal Importance of the Research Achievements |
がん治療後に必要な情報として、(i)早期再発予測、(ii)治療効果判定、(iii)無再発確証、の3つは不可欠である。本課題では独自に開発したdPCRプローブライブラリー技術をもとに「腫瘍で同定された体細胞変異をctDNAとしてdPCRを用いて追跡する手法」を用いて、がん治療後に必要な情報をどのような悪性腫瘍にも提供できると考えた。一方で、臓器、薬剤、測定する遺伝子、および再発形式によるctDNAの臨床的意義の違いは解明されていない。本研究により、ctDNAの臨床応用がより現実的なものになると考えられる。
|
